MAPT and Alzheimer disease: In addition, intravenous immunoglobulin was a classical immunotherapy and potentially reduces AD-type pathology by anti-Aβ, anti-tau, anti-inflammatory effects, and non-antibody-mediated effects [47,48], a chronic brain disease which is clinically characterized by cognitive dysfunction and has also been discussed with a link to the immunological hypothesis.